975
Views
13
CrossRef citations to date
0
Altmetric
Research Article

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers

, , , , , , , & show all
Pages 190-198 | Received 15 Feb 2013, Accepted 29 Apr 2013, Published online: 07 Jun 2013

References

  • Barouch DH, McKay PF, Sumida SM, et al. (2003). Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77:8729–35
  • Basile G, Peticca M. (2009). Recombinant protein expression in Leishmania tarentolae. Mol Biotechnol 43:273–8
  • Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, et al. (2005). A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16 induced tumors. J Immunol 175:7297–302
  • Biswas C, Sriram U, Ciric B, et al. (2006). The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells. Int Immunol 18:1147–57
  • Bolhassani A, Mohit E, Rafati S. (2009). Different spectra of therapeutic vaccine development against HPV infections: a review. Human Vaccines 5:1--11
  • Bolhassani A, Rafati S. (2008). Heat shock proteins as powerful weapons in vaccine development: a review. Expert Rev Vaccine 7:1185–99
  • Bolhassani A, Taheri T, Taslimi Y, et al. (2011). Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 127:637–45
  • Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. (2008). Enhanced immunogenicity of HPV16 E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 26:3362–70
  • Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. (2005). Live non-pathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 73:6372–82
  • Breton M, Zhao C, Ouellette M, et al. (2007). A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J Gen Virol 88:217–25
  • Cassetti MC, McElhiney SP, Shahabi V, et al. (2004). Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22:520–7
  • Chandawarkar RY, Wagh MS, Kovalchin JT, Srivastava P. (2004). Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int Immunol 16:615–24
  • Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. (2005). Cell-surface display of E7 antigen from human papillomavirus type 16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target 13:89–98
  • Devaraj K, Gillison ML, Wu TC. (2003). Development of HPV Vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 14:345–62
  • El-Aneed A. (2004). An overview of current delivery systems in cancer gene therapy. J Control Release 94:1–14
  • Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. (2007). Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 56:997–1007
  • He YF, Wang XH, Zhang GM, et al. (2005). Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 54:891–7
  • Held G, Neumann F, Sturm C, et al. (2008). Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. Int J Cancer 123:1841–7
  • Ji H, Chang EY, Lin KY, et al. (1998). Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 78:41–5
  • Jin HS, Park EK, Lee JM, et al. (2005). Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 97:559–67
  • Junqueira C, Santos LI, Galvão-Filho B, et al. (2011). Trypanosoma cruzi as an effective cancer antigen delivery vector. PNAS 108:19695–700
  • Kanodia S, Silva DMD, Kast WM. (2008). Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122:247–59
  • Kmieciak M, Knutson KL, Dumur CI, Manjili MH. (2007). Her2/neu antigen loss and relapse of mammary carcinoma are activity induced by T cell mediated anti-tumor immune responses. Eur J Immunol 37:675–85
  • Krul MR, Tijhaar EJ, Kleijne JA, et al. (1996). Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 43:44–8
  • Lamikanra A, Pan ZK, Isaacs SN, et al. (2001). Regression of established human papillomavirus type 16 (HPV 16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV16E7 correlates with enhanced CD8+ T cell responses that home to the tumor site. J Virol 75:9654–64
  • Li Y, Subjeck J, Yang G, et al. (2006). Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 24:5360–70
  • Lin K, Doolan K, Hung CF, Wu TC. (2010). Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 109:4–24
  • Mizbani A, Taheri T, Zahedifard F, et al. (2009). Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28:53–62
  • Mohit E, Bolhassani A, Zahedifard F, et al. (2012). Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol Immunol 53:149–60
  • Pakravan N, Soleimanjahi H, Hassan ZM. (2010). Gp96 C-terminal improves Her2/neu DNA vaccine. J Gene Med 12:345–53
  • Ravindran R, Maji M, Ali N. (2012). Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol Pharm 9:59–70
  • Robert J. (2003). Evolution of heat shock protein and immunity. Dev Comparative Immunol 27:449–64
  • Salehi M, Taheri T, Mohit E, et al. (2012). Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy 4:1107–20
  • Seo SH, Jin HT, Park SH, et al. (2009). Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic anti-tumor effect by antigen engineering and electroporation. Vaccine 27:5906–12
  • Sewell DA, Pan ZK, Paterson Y. (2008). Listeria-based HPV16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV16 transformed tumors. Vaccine 26:5315–20
  • Srivastava P. (2002). Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395--425
  • Yan J, Liu X, Wang Y, et al. (2007). Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of Gp96. J Gene Med 9:107–21

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.